{
    "root": "15dd0555-b33f-4f56-94d3-0f4ce888df01",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "Human Prescription Drug Label",
    "name": {
        "text": "Sunitinib Malate"
    },
    "value": "20250210",
    "ingredients": [
        {
            "name": "SUNITINIB MALATE",
            "code": "LVX8N1UT73"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        }
    ],
    "indications": "sunitinib malate capsule kinase inhibitor indicated : treatment adult patients gastrointestinal stromal tumor ( gist ) disease progression intolerance imatinib mesylate . ( 1.1 ) treatment adult patients advanced renal cell carcinoma ( rcc ) . ( 1.2 ) adjuvant treatment adult patients high risk recurrent rcc following nephrectomy . ( 1.3 ) treatment progressive , well-differentiated pancreatic neuroendocrine tumors ( pnet ) adult patients unresectable locally advanced metastatic disease . ( 1.4 )",
    "contraindications": "gist advanced rcc : recommended 50 mg orally daily first 4 weeks 6-week cycle ( schedule 4/2 ) . ( 2.1 ) adjuvant treatment rcc : recommended 50 mg orally daily first 4 weeks 6-week cycle ( schedule 4/2 ) maximum 9 cycles . ( 2.2 ) pnet : recommended 37.5 mg orally daily . ( 2.3 )",
    "warningsAndPrecautions": "sunitinib malate 12.5 mg capsules supplied size “ 4 ” hard gelatin capsules orange opaque body imprinted “ 6 ” orange opaque cap imprinted “ multiple sclerosis ” white ink : bottles 28 capsules : ndc 72205-116-28 sunitinib malate 25 mg capsules supplied size “ 3 ” hard gelatin capsules orange opaque body imprinted “ 7 ” caramel opaque cap imprinted “ multiple sclerosis ” white ink : bottles 28 capsules : ndc 72205-117-28 sunitinib malate 37.5 mg capsules supplied size “ 3 ” hard gelatin capsules yellow opaque body imprinted “ 8 ” yellow opaque cap imprinted “ multiple sclerosis ” black ink : bottles 28 capsules : ndc 72205-118-28 sunitinib malate 50 mg capsules supplied size “ 2 ” hard gelatin capsules caramel opaque body imprinted “ 9 ” caramel opaque cap imprinted “ multiple sclerosis ” white ink : bottles 28 capsules : ndc 72205-119-28 store 20° 25°c ( 68° 77°f ) ; excursions permitted 15°c 30°c ( 59°f 86°f ) [ usp controlled room temperature ] .",
    "adverseReactions": "none .",
    "indications_original": "Sunitinib malate capsule is a kinase inhibitor indicated for: treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. ( 1.1 ) treatment of adult patients with advanced renal cell carcinoma (RCC). ( 1.2 ) adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy. ( 1.3 ) treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in adult patients with unresectable locally advanced or metastatic disease. ( 1.4 )",
    "contraindications_original": "GIST and Advanced RCC: The recommended dosage is 50 mg orally once daily for the first 4 weeks of each 6-week cycle (Schedule 4/2). ( 2.1 ) Adjuvant Treatment of RCC: The recommended dosage is 50 mg orally once daily for the first 4 weeks of a 6-week cycle (Schedule 4/2) for a maximum of 9 cycles. ( 2.2 ) pNET: The recommended dosage is 37.5 mg orally once daily. ( 2.3 )",
    "warningsAndPrecautions_original": "Sunitinib malate 12.5 mg capsules are supplied as Size “4” hard gelatin capsules with orange opaque body imprinted with “6” and orange opaque cap imprinted with “MS” in white ink: Bottles of 28 capsules: NDC 72205-116-28 Sunitinib malate 25 mg capsules are supplied as Size “3” hard gelatin capsules with orange opaque body imprinted with “7” and caramel opaque cap imprinted with “MS” in white ink: Bottles of 28 capsules: NDC 72205-117-28 Sunitinib malate 37.5 mg capsules are supplied as Size “3” hard gelatin capsules with yellow opaque body imprinted with “8” and yellow opaque cap imprinted with “MS” in black ink: Bottles of 28 capsules: NDC 72205-118-28 Sunitinib malate 50 mg capsules are supplied as Size “2” hard gelatin capsules with caramel opaque body imprinted with “9” and caramel opaque cap imprinted with “MS” in white ink: Bottles of 28 capsules: NDC 72205-119-28 Store at 20° to 25°C (68° to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "None."
}